HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Capitol Hill In Brief

This article was originally published in The Tan Sheet

Executive Summary

Congress passes CR with cuts to FDA

You may also be interested in...

FDA's Hamburg Says Japanese Crisis Shows Need To Fund Countermeasure Development

When Senators ask whether the U.S. is prepared for a nuclear disaster similar to one following the Japanese earthquake, FDA chief touts agency program that could help develop radiation treatments.

Sharp Cuts In FDA's Fiscal 2011 Funding Included In House GOP Plan

Funding for the rest of fiscal 2011 would drop 10.5% for FDA's center regulating OTC drugs and 7.3% for the center with dietary supplement oversight under a Republican-drafted plan the House is considering.

Bills Would Overturn Rx Requirement For OTC Purchases From FSAs

Members of Congress will introduce targeted bills to overturn a provision of health care reform that requires consumers to get a prescription for OTC drugs to use money from pre-tax health savings accounts.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts